My Adherence Program by Lumara Health™

A program designed to support you
throughout your pregnancy.

As a mom who has been prescribed Makena® (hydroxyprogesterone caproate injection), you now have access to My Adherence Program, a free weekly over-the-phone program designed to help encourage adherence with your weekly Makena® (hydroxyprogesterone caproate injection) injections.

By simply filling out the form below to sign up for the program, you’ll be assigned your own maternal health nursing specialist who will be by your side through your pregnancy journey to help you stay on track with your injections, provide educational information, and answer questions.

Every week counts during your pregnancy to help your baby grow and develop. With Makena and My Adherence Program, you are taking important steps toward achieving this goal.

Thank you for your interest in the My Adherence Program. Based on your responses, the program can support your Makena® (hydroxyprogesterone caproate injection) treatment.  Please read the Program Authorization message, and confirm your interest in the My Adherence Program

Program Authorization

As a patient who has been prescribed Makena® (hydroxyprogesterone caproate injection),  I have access to My Adherence Program (“Program”), a program designed to help me stay on track with treatment and provide me with educational information throughout my pregnancy. I understand that my participation in the Program will mean that I may be contacted via phone, email, and mail by representatives of Envolve People Care, Inc. a division of Centene Corporation and business partner of AMAG Pharmaceuticals that administers the Program. By signing below, I acknowledge that I am voluntarily choosing to participate in this Program and I understand that my failure to enroll in the Program will not affect my treatment with Makena® (hydroxyprogesterone caproate injection) or eligibility for any benefits that I may be eligible to receive.

If I decide to participate in the Program, I understand and agree that the data provided to Envolve People Care, Inc. which may include Protected Health Information will be specifically identifiable to me or my baby and will be used by Envolve People Care, Inc. solely in the provision of the Program. I further understand that any data collected in the provision of those services for uses outside of the Program will be de-identified and will not be specifically identifiable to me or my baby, and may be used by Envolve People Care, Inc., AMAG Pharmaceuticals or their affiliated companies and agents for their internal business purposes. I further acknowledge and give permission for these entities to publish such data in an aggregate format in a medical journal or other similar publication. I understand that I may discontinue participation in the Program or withdraw my consent to use my medical information at any time, by calling 1-844-660-0867; or writing My Adherence Program by AMAG Pharmaceuticals, c/o Envolve People Care, Inc., 2900 Pershall Rd, St. Louis, MO 63136.

Please confirm your full name to confirm that you wish to enroll in the My Adherence Program by Lumara Health.

Thank you. Your confirmation has been recorded. You will receive a call from a Maternal Health Nursing Specialist within 2 business days to complete your enrollment.

Thank you for your interest in the My Adherence Program by AMAG Pharmaceuticals. Based on your responses, the program can support your Makena® (hydroxyprogesterone caproate injection) treatment.  Please read the Program Authorization message, and confirm your interest in the My Adherence Program by AMAG Pharmaceuticals.

Thank you for your interest in the My Adherence Program by AMAG Pharmaceuticals. Based on your responses, we need to gather further information from you to determine if the program supports your treatment. You will receive a call from a Maternal Health Nursing Specialist within 2 business days. 

Thank you for your interest in the My Adherence Program by AMAG Pharmaceuticals.  Participants in the My Adherence Program need to meet the FDA-approved indication for therapy. Based on your responses, we are unable to provide this service.  If you have any questions about this message, please call a Maternal Health Nursing Specialist at 1-844-660-0867.

Important safety information for Makena (hydroxyprogesterone caproate injection)

Makena should not be used in women with any of the following conditions: blood clots or other blood clotting problems, breast cancer or other hormone-sensitive cancers, or history of these conditions; unusual vaginal bleeding not related to your current pregnancy, yellowing of the skin due to liver problems during pregnancy, liver problems, including liver tumors, or uncontrolled high blood pressure.

Before you receive Makena, tell your healthcare provider if you have an allergy to hydroxyprogesterone caproate, castor oil, or any of the other ingredients in Makena; diabetes or prediabetes, epilepsy, migraine headaches, asthma, heart problems, kidney problems, depression, or high blood pressure.

In a clinical study, certain complications or events associated with pregnancy occurred more often in women who received Makena. These included miscarriage (pregnancy loss before 20 weeks of pregnancy), stillbirth (fetal death occurring during or after the 20th week of pregnancy), hospital admission for preterm labor, preeclampsia (high blood pressure and too much protein in your urine), gestational hypertension (high blood pressure caused by pregnancy), gestational diabetes, and oligohydramnios (low amniotic fluid levels).

Makena may cause serious side effects including blood clots, allergic reactions, depression, and yellowing of your skin and the whites of your eyes. Call your healthcare provider right away if you think you have symptoms of a blood clot (leg swelling, redness in your leg, a spot on your leg that is warm to touch, or leg pain that worsens when you bend your foot) or symptoms of an allergic reaction (hives, itching, or swelling of the face). The most common side effects of Makena include injection site reactions (pain, swelling, itching, bruising, or a hard bump), hives, itching, nausea, and diarrhea.

You are encouraged to report negative side effects of prescription drugs to the FDA.

Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Please see full Makena prescribing information.

Indication

Makena (hydroxyprogesterone caproate injection) is a prescription hormone medicine (progestin) used to lower the risk of preterm birth in women who are pregnant with one baby and who have delivered one baby too early (preterm) in the past. Makena was shown to work based on a lower number of women who delivered babies at less than 37 weeks of pregnancy. There are no studies showing Makena reduces the number of babies who have serious problems shortly after birth or who die. It is not known whether Makena is safe and effective in women who have other risk factors for preterm birth.

Important safety information for Makena (hydroxyprogesterone caproate injection)

Makena should not be used in women with any of the following conditions: blood clots or other blood clotting problems, breast cancer or other hormone-sensitive cancers, or history of these conditions; unusual vaginal bleeding not related to your current pregnancy, yellowing of the skin due to liver problems during pregnancy, liver problems, including liver tumors, or uncontrolled high blood pressure.

Before you receive Makena, tell your healthcare provider if you have an allergy to hydroxyprogesterone caproate, castor oil, or any of the other ingredients in Makena; diabetes or prediabetes, epilepsy, migraine headaches, asthma, heart problems, kidney problems, depression, or high blood pressure.

In a clinical study, certain complications or events associated with pregnancy occurred more often in women who received Makena. These included miscarriage (pregnancy loss before 20 weeks of pregnancy), stillbirth (fetal death occurring during or after the 20th week of pregnancy), hospital admission for preterm labor, preeclampsia (high blood pressure and too much protein in your urine), gestational hypertension (high blood pressure caused by pregnancy), gestational diabetes, and oligohydramnios (low amniotic fluid levels).

Makena may cause serious side effects including blood clots, allergic reactions, depression, and yellowing of your skin and the whites of your eyes. Call your healthcare provider right away if you think you have symptoms of a blood clot (leg swelling, redness in your leg, a spot on your leg that is warm to touch, or leg pain that worsens when you bend your foot) or symptoms of an allergic reaction (hives, itching, or swelling of the face). The most common side effects of Makena include injection site reactions (pain, swelling, itching, bruising, or a hard bump), hives, itching, nausea, and diarrhea.

You are encouraged to report negative side effects of prescription drugs to the FDA.

Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Please see full Makena prescribing information.

Indication

Makena (hydroxyprogesterone caproate injection) is a prescription hormone medicine (progestin) used to lower the risk of preterm birth in women who are pregnant with one baby and who have delivered one baby too early (preterm) in the past. Makena was shown to work based on a lower number of women who delivered babies at less than 37 weeks of pregnancy. There are no studies showing Makena reduces the number of babies who have serious problems shortly after birth or who die. It is not known whether Makena is safe and effective in women who have other risk factors for preterm birth.